ClinicalTrials.gg
RecruitingNCT07302048MoDIDolUpdated Dec 24, 2025

Impact and Determinants of Success of a Mobile Multidisciplinary Intervention System Specialized in Pain Management for Patients With Moderate to Severe Intellectual Development Disorder, Isolated or Associated With an ASD or Multiple Disability

An interventional study of MoDIDol intervention in Autism Disorder, Multiple Disabilities and Pain, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged Up to 24 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
Up to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.

Planned enrollment
15th of 37
80 · median 60
Started
2025
with 2 others
No phase
26 of 50
7 open now
Registered
47th of 50
by date
Lead sponsor
4 of 50
University Hospital, Brest

Among the 50 studies in Autistic Disorder with a site in France, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 26 with no phase, and was the 47th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: Up to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Autistic Disorder with a site in France, or all of them as a file.
02

Study summary

Pain is described by patients with a Neurodevelopmental Disorder (NDD), including Autism Spectrum Disorder (ASD), Intellectual Development Disorder (IDD) or multiple disabilities, and the family as one of the main associated disorders; its management is also one of the main concerns of families and professionals. At present, there is no validated and tested pain management system in populations facing complex pain situations. In response to the lack of a pain management services, a multi-disciplinary mobile team was set up in September 2022 at the Brest University Hospital (Mobile Pain Handicap Team Intellectual Disability 0-25 years; MoDIDol). This team offers a specific protocol for the assessment and management of pain that takes into account the social and family environment, the living context and the clinical characteristics of patients (children, adolescents and young adults (0-25 years) with IDD, ASD or multiple disabilities). The team includes at least one paediatrician specialising in the assessment and treatment of pain and a nurse, and travels to patients' usual living environments.

Read the detailed description

The MoDIDol team intervenes at the request of parents or professionals in complex situations involving pain or behavioural problems suggestive of pain, unresolved despite previous treatment. Parents and professionals learn about the MoDIDol team through flyers and information provided by associations and organisations supporting people with disabilities (associations, CRDI, etc.).

Once they are included in the study and after consent has been signed, multidisciplinary follow-up consultations are carried out by the MoDIDol team for pain management (every 6 weeks).

At the same time, three data collection sessions are planned for the participants, 3 months apart. Questionnaires are completed at each point by dedicated study staff. Interviews are conducted at 6-month intervals among a representative sample of professionals and parents.

03

Conditions studied

  • Autism Disorder
  • Multiple Disabilities
  • Pain
  • Intellectual Developmental Disorder

Keywords

  • Pain
  • Children
  • Adolescents
  • young adults
  • Intellectual Developmental Disability
  • Autism Spectrum Disorder
  • multiple disabilities
  • mobile team
04

Who can participate

Ages eligible
Up to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged from birth up to 24 years inclusive (i.e., under 25 years old)
  • Medical diagnosis of intellectual disability (ID), isolated or associated with autism spectrum disorder (ASD), developmental disorder (DD), or profound multiple disabilities, based on international classification systems (ICD-11 or )
  • Confirmed probable or definite pain diagnosis, as validated by the MoDIDol team
  • PGIC score ≥ 3
  • Living in or receiving care in the departments of Finistère, Côtes-d'Armor, or Morbihan
  • Written provided by parents, legal guardians, or holders of parental authority, authorizing data collection for research and publication purposes
  • Affiliated with or benefiting from a French national health insurance scheme

Exclusion criteria

Exclusion Criteria:

  • More than three places of residence and/or care settings
  • Parents or legal guardians who do not have sufficient language or comprehension skills to provide or complete study questionnaires
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    children or young adults with IDD, ASD or multiple disabilities

    Single arm study Interventions are : * parents education for NCCPC and PPP by a pain specialized nurse at T1 * parents fullfilling of questionnaires à T1, T2 and T3 with study engineer

    Procedure: MoDIDol intervention

Interventions

  • ProcedureMoDIDol intervention

    Multidisciplinary mobile intervention system specialising in pain management for patients with moderate to severe intellectual development disorders, isolated or associated with ASD or multiple disabilities. Treatment recommendations, pain assessment, training in scales, follow-up consultations every 6 weeks for 6 months, continued if the situation is not resolved, call at 12 months.

06

What researchers measure

Primary outcomes

  1. Global Clinical Improvement at 6 months

    The primary outcome is the patient's global clinical improvement as perceived by family caregivers and/or institutional professionals, using the Patient Global Impression of Change (PGIC) scale after 6 months of care provided by the MoDIDol team. Improvement is defined as a PGIC score of 1 or 2 out of 7. scale from 1 to 7, higher scores mean worse outcome.

    Time frame: From baseline to the end of 6 months of treatment with the MoDIDol system, assessed up to 6 months (T3)

Secondary outcomes

  1. Global Clinical Improvement at 3 months

    Global clinical improvement of the patient, as reported by caregivers and/or professionals, measured using the Patient Global Impression of Change (PGIC) scale after 3 months of MoDIDol care. Improvement is defined as a PGIC score of or 2 out of 7. Scale from 1 to 7, higher scores mean worse outcome.

    Time frame: From baseline to the end of 3 months of treatment with the MoDIDoL system, assessed up to 3 months (T2)

  2. Non Communicating Children's Pain Checklist (NCCPC) Pain Intensity Scores at T1, T2, and T3

    Pain intensity will be assessed using the french version of Non Communicating Children's Pain Checklist (NCCPC) scale at baseline (T1), 3 months (T2), and 6 months (T3). The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.

  3. Pediatric Pain Profile (PPP) Pain Intensity Scores at T1, T2, and T3

    Pain intensity will be assessed using the french version of Pediatric Pain Profile (PPP) scale at baseline (T1), 3 months (T2), and 6 months (T3). 20 behaviors are to be rated from 0 = not at all to 3 = completely. Pain is moderate to severe if score is 14/60 or above.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.

  4. Non Communicating Children's Pain Checklist (NCCPC) Pain Category Change

    Patients will be categorized based on the french version of Non Communicating Children's Pain Chlecklist (NCCPC) (\<6 : no pain; 6 to10 : mild pain; \>10 : moderate to severe pain) scores to evaluate changes in pain category from T1 to T2 and T2 to T3. The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  5. Pediatric Pain Profile Pain Category Change

    Patients will be categorized based on french version of Pediatric Pain Profile (PPP) (\<14; \> or =14) scores to evaluate changes in pain category from T1 to T2 and T2 to T3. Twenty behaviors are to be rated from 0 = not at all to 3 = completely. Pain is moderate to severe if score is 14/60 or above.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  6. Non Communicating Children's Pain Checklist (NCCPC) Pain Behavior Profiles

    Behavioral indicators of pain will be documented using the item-based responses from Non Communicating Children's Pain Checklist (NCCPC) scale at T1. The full rating is based on a 90-point scale : 4-point scale (0 : not observed ; 3 : frequently) for 30 behavioral assessments. But some behaviors can be omitted when non applicable (NA). Pain is mild if score is between 6 and 10, and moderate to severe if score is 11 or more.

    Time frame: Baseline (T1)

  7. Pediatric Pain Profile Pain Behavior Profiles

    Behavioral indicators of pain will be documented using the item-based responses from Pediatric Pain Profile (PPP) scale at T1. Behaviours are to be assessed from 0 = not at all to 3 = completely (score from 0 to 60; pain if score \> 14).

    Time frame: Baseline (T1)

  8. Behavioral Disturbance Evolution

    Frequency (0:never to 4: At least once an hour) and severity (1: mild to 3: severe) of three types of behaviors (self-injurious behaviors, stereotypical behaviors, and aggressive/destructive behaviors) will be assessed with the Behavior Problems Inventory (BPI) scale at T1, T2, and T3.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system.

  9. PedsQL Patient Quality of Life Scores

    Quality of life will be assessed using Pediatric Quality of Life Inventory (PedsQL) for patients without profound disabilities on a five-point Likert scale (from 0: Never/Bad; to 4: Almost Always/Excellent) for 15 items at T1, T2, and T3.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  10. PolyQoL Patient Quality of Life Scores

    Quality of life will be assessed using Quality of Life Scale for People with polyhandicap (PolyQoL) for patients with profound multiple disabilities on a five-point Likert scale (from 1: very bad; to 5: very goodt) for 21 items at T1, T2, and T3.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  11. Sleep Quality Scores

    Sleep disorders will be measured with the Sleep Disturbance Scale for Children (SDSC) scale on a five-point Likert scale (from 1: never; to 5: every day) for 25 items at T1, T2, and T3.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  12. Parental Quality of Life

    Parental quality of life will be assessed using the World Health Organization Quality of Life (WHOQOL-BREF) across four domains rated on a 5-point Likert scale (score from 1 to 5) for 26 items at T1, T2, and T3.

    Time frame: Baseline (T1), after 3 months (T2), and 6 months (T3) of treatment with the MoDIDol system

  13. Parental Stress

    Parental stress will be evaluated using the Parenting Stress Index (PSI-4) at T1, T2, and T3. This questionnaire includes 120 items divided in two categories (stressors associated with the child domain, or with de parent domain) rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree". The total score of stress is obtained by adding up the results. The higher the value is, the higher the stress.

    Time frame: Baseline (T1), 3 months (T2), and 6 months (T3)

  14. Determinants of Success

    Individual (e.g., diagnosis, development level, sensory profile) and environmental (e.g., living environment, type of care) factors will be analyzed in relation to PGIC (Patient Global Impression of Change) score at T3.

    Time frame: From baseline to the end of 6 months of treatment with the MoDIDol system, assessed up to 6 months (T3)

  15. Pain Mechanism, Localization, and Etiology

    Pain causes will be described according to the mechanism (nociceptive, neuropathic, nociplastic), location, and etiology. Patients with intellectual deficiency are not able to describe their pain because of verbal impairment. Qualitative informations are available through parents and professionnal observations. Evaluation is based on physical examination, specialized medical advice (dental, ENT, ...) and additional examinations, such as laboratory or medical imaging, if needed. These description are build at T1 as hypothesis and may be specified depending on developments during treatment.

    Time frame: Pain mechanism, location and etiology are determined at T1 but can be revised during the 6 months patient follow up

  16. Analgesic and Behavioral Treatments

    Description of treatments (indication and dosage) for pain and behavior at T2 and T3.

    Time frame: From baseline to the end of 3 months (T2) and 6 months (T3) of treatment with the MoDIDol system

  17. Psychometric Properties of Non Communicating Children's Pain Checklist (NCCPC) Scale

    Internal consistency and structural validity of the french version of Non Communicating Children's Pain Checklist (NCCPC) (for patients with ASD) scale will be assessed.

    Time frame: Through study completion, an average of 6 months after baseline.

  18. Psychometric Properties of Pediaric Pain Profile Scale

    Internal consistency and structural validity of the french version of Pediatric Pain Profile (PPP) scale will be assessed.

    Time frame: Through study completion, an average of 6 months after baseline.

  19. Qualitative Interviews with Parents and Professionals

    Impact of MoDIDol will be assessed through semi-structured interviews before (T1) and after (T3) of the intervention. Themes include daily impact of pain, beliefs, use of pain assessment tools, and perceived value of the mobile team

    Time frame: Baseline (T1) and after 6 months (T3) of treatment with the MoDIDol system

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available after the publication of result and ending fifteen years following the last visit of the last patient

Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2028, 30 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 30 months is above that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Dec 24, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Apr 20, 2028
CompletionEst.
Apr 20, 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07302048
Collaborators
Fondation de France, Université de Bretagne Occidentale, Brest-France, Fondation Perce Neige
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Oct 14, 2025
Primary completion
Apr 20, 2028 (estimated)
Completion
Apr 20, 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Philippe LE MOINE, MD
Contact
philippe.lemoine@chu-brest.fr
+332 98 22 39 56
Philippe J LE MOINE, MD
principal investigator · CHU de Brest
Amandine DUBOIS, PhD
study director · Université de Bretagne Occidentale

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion